Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06117930 · ClinicalTrials.gov registry record
Study of Human Brain-Gut Axis and Gut Microbiome in Patients With Brain Lesions - Repository for Neuroscience Research
A clinical trial of Malignant Central Nervous System Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06117930 is a study of Malignant Central Nervous System Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 1,770-participant average among 3 other Malignant Central Nervous System Neoplasm trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06117930, a study of Malignant Central Nervous System Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study explores how microorganisms in the gut can affect the growth and progression of brain tumors.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-02-28 |
| Est. Completion | 2029-12-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06117930
The ClinicalTrials.gov registry entry for NCT06117930 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,770-participant average among 3 other Malignant Central Nervous System Neoplasm trials with a reported enrollment target (94% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Central Nervous System Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06117930 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06117930 about?
NCT06117930 is a clinical study titled "Study of Human Brain-Gut Axis and Gut Microbiome in Patients With Brain Lesions - Repository for Neuroscience Research". This study explores how microorganisms in the gut can affect the growth and progression of brain tumors.
What is the current status of trial NCT06117930?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-02-28. Estimated completion is 2029-12-13.
What conditions does trial NCT06117930 study?
This clinical trial studies the following conditions: Malignant Central Nervous System Neoplasm.
What interventions are being tested in trial NCT06117930?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06117930?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06117930 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Central Nervous System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.